The subjects must meet the following criteria for registration:

Enroll prospectively (patient is still pregnant and no structural defects have been noted on a prenatal test)

Exposure to Keppra® and Keppra XR® on or after the first day of the patient's last menstrual period (verified by date or gestational age of exposure)

For patient-initiated enrollments, provide verbal or written consent to participate in the Registry

For patient-initiated enrollments, provide contact information for herself, her HCP, and the infant's HCP (as applicable)

UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)